A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Study sponsor: Nektar Therapeutics · NKTR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-05Estimated
Enrollment · participants510Estimated
Source updated2026-10-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.